Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients: An Open-label, Randomized, add-on Study.
Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 09 Jun 2015
Price : $35 *
At a glance
- Drugs Paroxetine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 15 Jul 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 16 Aug 2013 Planned initiation date changed from 1 Sep 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 09 Aug 2013 New trial record